-
公开(公告)号：US20070043102A1
公开(公告)日：2007-02-22
申请号：US10551218
申请日：2004-03-30
IPC分类号： A61K31/405 , A61K47/00
CPC分类号： A61K9/0095 , A61K31/4045 , A61K47/46
摘要： This invention relates to an oral suspension of tegaserod or pharmaceutically acceptable salts thereof. In particular, it relates to an oral suspension comprising a power comprising an effective amount otegaserod or a pharmaceutically acceptable salt thereof in a beverage, e.g. apple juice.
摘要翻译： 本发明涉及替加色罗或其药学上可接受的盐的口服悬浮液。 特别地，本发明涉及一种口服悬浮液，其包含在饮料中包含有效量的奥替加他乐或其药学上可接受的盐的功能。 苹果汁。
-
2.发明申请Pharmaceutical combinations and their use in treating gastrointestinal and abdominal viscera disorders 审中-公开药物组合及其在治疗胃肠和腹部脏器障碍中的应用公开(公告)号：US20080090878A1
公开(公告)日：2008-04-17
申请号：US11973404
申请日：2007-10-09
申请人： Stephan Billstein , Peter Dumovic , Nicola Franco , Mark Iwicki , Hans-Juergen Pfannkuche , Edward Wilusz
发明人： Stephan Billstein , Peter Dumovic , Nicola Franco , Mark Iwicki , Hans-Juergen Pfannkuche , Edward Wilusz
IPC分类号： A61K31/404 , A61K31/4439 , A61P1/00
CPC分类号： A61K45/06 , A61K31/404 , A61K31/4439 , A61K31/445 , A61K31/5513 , A61K2300/00
摘要： The present invention relates to a combination of a first agent including either a 5-HT4 receptor agonist or antagonist or a 5-HT3 receptor antagonist and a co-agent and pharmaceutical compositions and formulations containing the combination. The present invention also relates to a method of treating a gastrointestinal and abdominal viscera disorder by administering the pharmaceutical compositions to a patient. The pharmaceutical compositions may also be employed as laxatives, to prepare a patient for colonoscopy and to regulate and stabilize enterochromaffin cell secretory, pain and motility mechanisms, afferent fiber activity and GI and lower abdominal smooth muscle cells. The dosage is preferably oral and administration is preferably once or twice a day. The preferred first agent is tegaserod.
摘要翻译： 本发明涉及包含5-HT 4受体激动剂或拮抗剂或5-HT 3受体拮抗剂的第一药剂与助剂和 药物组合物和含有该组合的制剂。 本发明还涉及通过向患者施用药物组合物来治疗胃肠和腹部脏器障碍的方法。 药物组合物也可以用作泻药，以制备用于结肠镜检查的患者，并且调节和稳定肠嗜铬细胞分泌，疼痛和运动机制，传入纤维活性和GI和下腹部平滑肌细胞。 剂量优选为口服，并且优选每天施用一次或两次。 优选的第一剂是替加色罗。
-
搜索结果
2 条记录 (耗时 0.013 秒)
